Myriad's Flurizan Deal Is a Hedged Bet (at TheStreet.com)
yahoo.com     22-May-2008            

Myriad Genetics MYGN surprised investors early Thursday selling outside-the-U.S. rights to its Alzheimer's drug Flurizan -- mere weeks before late-stage data will offer more clues to the drug's approvability. Danish company Lundbeck will pay Myriad $100 million upfront... [read full story]                    


View all news articles about*:
Genetics Myriad
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Pfizer Gambles On Russian Alzheimer's Pill

pharmiweb.co.uk     03-Sep-2008   25 related          

Robert Langreth 09.03.08, 4:30 PM ET It has been a rough year for many companies testing new Alzheimer's disease drugs. A former antihistamine sold in Russia called Dimebon showed strong results in an initial efficacy...                    

comments

                   

EpiCept Regains Compliance with Nasdaq Listing Rule

euroinvestor.co.uk     28-Aug-2008   2 related          

Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has been deemed in compliance with the Nasdaq Hearings Panel’s decision dated August 6, 2008 and that accordingly, the...                    

comments